Abstract

Direct oral anticoagulants (DOACs) are increasingly used in the treatment and prophylaxis of thromboembolism because of several advantages over vitamin K antagonists, including no need for laboratory monitoring. However, it has become increasingly important in certain clinical scenarios to know either actual DOAC concentration (quantitative) or presence of DOAC (qualitative). These clinical conditions include patients presenting with major bleeding or requiring urgent surgery who may need a reversal or hemostatic agent, extremes of body weight, failed therapy, etc. Prothrombin time and activated partial thromboplastin time are variably affected by factor Xa inhibitors (FXaIs) and direct thrombin inhibitor (DTI), respectively, depending on reagents’ sensitivity, and hence, they cannot be relied on confidently. Thrombin time is highly sensitive to very low amounts of DTI; thus, normal value rules out a clinically significant amount. Liquid chromatography mass spectrometry accurately measures DOAC levels but is clinically impractical. Dilute thrombin time and ecarin-based assays using appropriate calibrators/controls provide an accurate DTI level. Anti-Xa assay using corresponding FXaI calibrators/controls provides accurate drug levels. However, these assays are not readily available in the United States compared with some other parts of the world. Heparin assays using anti-Xa activity often have a linear relationship with calibrated FXaI assays, especially at the lower end of on-therapy levels, and they may provide rapid assessment of drug activity for clinical decision making. Currently, there is very limited knowledge of DOAC effect on viscoelastic measurements. Although there is uniformity in expression of DOAC concentrations in nanograms per milliliter, a universal FXaI DOAC assay is urgently needed.

References

References
1.
Testa
S
,
Paoletti
O
,
Legnani
C
, et al
.
Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants
.
J Thromb Haemost
.
2018
;
16
(
5
):
842
-
848
.
2.
Cuker
A
,
Burnett
A
,
Triller
D
, et al
.
Reversal of direct oral anticoagulants: guidance from the Anticoagulation Forum
.
Am J Hematol
.
2019
;
94
(
6
):
697
-
709
.
3.
Gosselin
RC
,
Adcock
DM
,
Bates
SM
, et al
.
International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants
.
Thromb Haemost
.
2018
;
118
(
3
):
437
-
450
.
4.
Tripodi
A
,
Ageno
W
,
Ciaccio
M
, et al
.
Position paper on laboratory testing for patients on direct oral anticoagulants. A consensus document from the SISET, FCSA, SIBioC and SIPMeL
.
Blood Transfus
.
2018
;
16
(
5
):
462
-
470
.
5.
Patel
JP
,
Byrne
RA
,
Patel
RK
,
Arya
R
.
Progress in the monitoring of direct oral anticoagulant therapy
.
Br J Haematol
.
2019
;
184
(
6
):
912
-
924
.
6.
Tomaselli
GF
,
Mahaffey
KW
,
Cuker
A
, et al
.
2017 ACC Expert Consensus Decision Pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways
.
J Am Coll Cardiol
.
2017
;
70
(
24
):
3042
-
3067
.
7.
Levy
JH
,
Ageno
W
,
Chan
NC
,
Crowther
M
,
Verhamme
P
,
Weitz
JI
;
Subcommittee on Control of Anticoagulation
.
When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH
.
J Thromb Haemost
.
2016
;
14
(
3
):
623
-
627
.
8.
Connolly
SJ
,
Crowther
M
,
Eikelboom
JW
, et al
;
ANNEXA-4 Investigators
.
Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors
.
N Engl J Med
.
2019
;
380
(
14
):
1326
-
1335
.
9.
Yates
SG
,
Smith
S
,
Tharpe
W
,
Shen
YM
,
Sarode
R
.
Can an anti-Xa assay for low-molecular-weight heparin be used to assess the presence of rivaroxaban?
Transfus Apher Sci
.
2016
;
55
(
2
):
212
-
215
.
10.
Sabor
L
,
Raphaël
M
,
Dogné
JM
,
Mullier
F
,
Douxfils
J
.
Heparin-calibrated chromogenic anti-Xa assays are not suitable to assess the presence of significant direct factor Xa inhibitors levels
.
Thromb Res
.
2017
;
156
:
36
-
38
.
11.
Powell
J
,
Taylor
J
,
Garland
SG
.
Andexanet alfa: a novel factor Xa inhibitor reversal agent
.
Ann Pharmacother
.
2019
;
53
(
9
):
940
-
946
.
12.
FDA
.
ANDEXXA (coagulation factor Xa (recombinant), inactivated-zhzo). https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/andexxa-coagulation-factor-xa-recombinant-inactivated-zhzo. Accessed 19 September 2019
.
13.
Ruff
CT
,
Giugliano
RP
,
Braunwald
E
, et al
.
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial
.
Lancet
.
2015
;
385
(
9984
):
2288
-
2295
.
14.
Henskens
YMC
,
Gulpen
AJW
,
van Oerle
R
, et al
.
Detecting clinically relevant rivaroxaban or dabigatran levels by routine coagulation tests or thromboelastography in a cohort of patients with atrial fibrillation
.
Thromb J
.
2018
;
16
(
3
):
3
.
15.
Seyve
L
,
Richarme
C
,
Polack
B
,
Marlu
R
.
Impact of four direct oral anticoagulants on rotational thromboelastometry (ROTEM)
.
Int J Lab Hematol
.
2018
;
40
(
1
):
84
-
93
.
16.
Mahamad
S
,
Chaudhry
H
,
Nisenbaum
R
, et al
.
Exploring the effect of factor Xa inhibitors on rotational thromboelastometry: a case series of bleeding patients
.
J Thromb Thrombolysis
.
2019
;
47
(
2
):
272
-
279
.
17.
Testa
S
,
Tripodi
A
,
Legnani
C
, et al
;
START-Laboratory Register
.
Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: results observed in four anticoagulation clinics
.
Thromb Res
.
2016
;
137
:
178
-
183
.
18.
Wada
S
,
Toyoda
K
,
Sato
S
, et al
.
Anti-Xa Activity and event risk in patients with direct factor Xa inhibitors initiated early after stroke
.
Circ J
.
2018
;
82
(
11
):
2872
-
2879
.
19.
Hirsh Raccah
B
,
Rottenstreich
A
,
Zacks
N
, et al
.
Appropriateness of direct oral anticoagulant dosing and its relation to drug levels in atrial fibrillation patients
.
J Thromb Thrombolysis
.
2019
;
47
(
4
):
550
-
557
.
20.
van Pelt
LJ
,
Lukens
MV
,
Testa
S
,
Chatelain
B
,
Douxfils
J
,
Mullier
F
.
The DaXa-inhibition assay: a concept for a readily available, universal aXa assay that measures the direct inhibitory effect of all anti-Xa drugs
.
Thromb Res
.
2018
;
168
:
63
-
66
.
You do not currently have access to this content.